Evidence map›Paper›PMID 40950232›Full record

ArticlebioRxiv : the preprint server for biology2025

Respiratory viral infections prime accelerated lung cancer growth.

Wei Qian, Xiaoqin Wei, Andrew J Barros, Xiangyu Ye, Qing Yu, Samuel P Young, Eric V Yeatts, Yury Park, Chaofan Li, Gislane Almeida-Santos and 11 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Wei QianBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Xiaoqin WeiBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Andrew J BarrosDivision of Pulmonary & Critical Care Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Xiangyu YeDepartment of Pediatrics, University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA.
Qing YuBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Samuel P YoungBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Eric V YeattsBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Yury ParkBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Chaofan LiBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Gislane Almeida-SantosBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Jinyi TangBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Harish NarasimhanBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Nicole A KirkDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.
Ying LiDepartment of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
Li LiDepartment of Family Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Peter ChenWomen's Guild Lung Institute Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Jeffrey M SturekDivision of Pulmonary & Critical Care Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Kwon-Sik ParkDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.
Wei ChenDepartment of Pediatrics, University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA.
In Su CheonBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Jie SunBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0002-2347-4511

Funding

Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2M
Host cellular network governing the development of post SARS-CoV-2 tissue sequelaeR01AI147394 · NIAID · UNIVERSITY OF VIRGINIA · PI Jie Sun · 2020 to 2026
$4.7M
Molecular regulation of protective CD8 immunity against influenza infectionR01AI112844 · NIAID · UNIVERSITY OF VIRGINIA · PI SUN, JIE · 2015 to 2024
$4.5M
Elucidating the roles of alveolar macrophage inflammation and selfrenewal during influenza infectionR01AG069264 · NIA · UNIVERSITY OF VIRGINIA · PI Jie Sun · 2020 to 2026
$3.5M
Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with AsthmaR01AI176171 · NIAID · UNIVERSITY OF VIRGINIA · PI Jie Sun, WILLIAM GERALD TEAGUE · 2023 to 2026
$2.7M
Uncover mechanisms underlying the development of chronic lung sequelae post COVID-19R01HL170961 · NHLBI · UNIVERSITY OF VIRGINIA · PI Jie Sun, ROBERT VASSALLO · 2023 to 2026
$2.7M
Training in Cell and Molecular BiologyT32GM139787 · NIGMS · UNIVERSITY OF VIRGINIA · PI Bryce Paschal · 2021 to 2026
$2.5M
Targeting BCAT1 and branched-chain amino acid metabolism for the detection and prevention of SCLCU01CA224293 · NCI · UNIVERSITY OF VIRGINIA · PI PARK, KWON-SIK · 2018 to 2022
$2.2M
CD38, T cells and post viral lung sequelae during agingR01AG090337 · NIA · UNIVERSITY OF VIRGINIA · PI Jie Sun · 2025 to 2026
$1.3M
Immune-epithelial progenitor interactions drive age-associated dysplastic lung repair post viral pneumoniaF31HL170746 · NHLBI · UNIVERSITY OF VIRGINIA · PI NARASIMHAN, HARISH · 2023 to 2024
$86k
NCI NIH HHS T32 CA009109NCI NIH HHS U01 CA224293NHLBI NIH HHS F31 HL170746NHLBI NIH HHS R01 HL170961NIAID NIH HHS R01 AI112844NIAID NIH HHS R01 AI147394NIAID NIH HHS R01 AI176171NIAID NIH HHS T32 AI007496NIA NIH HHS R01 AG069264NIA NIH HHS R01 AG090337NIGMS NIH HHS T32 GM139787
6 · The paper itself

Abstract

The COVID-19 pandemic has highlighted long-term health concerns of viral pneumonia, yet its potential impact on cancer development and growth remains poorly understood. Here, we demonstrate that prior infection with SARS-CoV-2 or influenza virus promoted lung tumor progression by reprogramming the local immune landscape. Retrospective clinical analysis revealed that patients hospitalized with COVID-19 exhibited increased lung cancer incidence. Using multiple murine lung cancer models, we show that prior severe respiratory viral infections accelerated tumor growth and reduced survival. Mechanistically, prior viral pneumonia epigenetically remodeled the lung to establish a pro-tumor microenvironment, including the local accumulation of SiglecF

Identifiers

PMID40950232
PMCPMC12424724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.